Cholesterol drug paired with immunotherapy shows promise for tough kidney cancer

NCT ID NCT06284564

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding evolocumab (a cholesterol-lowering drug) to nivolumab (an immunotherapy) can help control metastatic kidney cancer that has not responded to prior treatments. Only 10 participants are enrolled, and the main goal is to check safety and side effects. The study is active but no longer recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: evolocumab and nivolumab
What this could lead to: If it works, this could point toward a new combination therapy for advanced kidney cancer that has stopped responding to other treatments.
What could go wrong: This is a very small, early-phase trial with only 10 participants, so results may not apply broadly. The main goal is safety, not yet proof of effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC RENAL CELL CARCINOMA

Contacts and locations

Locations

MD Anderson Cancer Center

Houston, Texas, 77030, United States
UT Southwestern Medical Center

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.